News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Mourad Tighiouart, PhD

Articles by Mourad Tighiouart, PhD

Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification

ByBethany Smith, PhD,Sungjin Kim, MS ,Mourad Tighiouart, PhD,Edwin M. Posadas, MD,Leland Chung, PhD,Robert A. Figlin, MD,Neil Bhowmick, PhD,Jun Gong, MD

September 14th 2021

This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.

Latest Updated Articles

Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification
September 14th 2021

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Achieving a “Functional Cure” With Multiple Myeloma Therapy

FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC